ArticleJournal of thoracic disease2026
Clinical impact and prognostic factors of early radiotherapy in limited-disease small-cell lung cancer cohort.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal timing of thoracic radiotherapy (RT) during concurrent chemoradiotherapy (CCRT) for small cell lung cancer (SCLC) remains controversial. This study aimed to evaluate treatment outcomes, prognostic factors, and the role of prophylactic cranial irradiation (PCI) according to thoracic RT timing in patients with limited-disease (LD) SCLC. Methods: A retrospective study was conducted on patients with SCLC diagnosed between 2018 and 2022. Survival outcomes, prognostic factors, treatment outcomes, and adverse events were assessed according to thoracic RT timing (early Results: Among 122 patients diagnosed with LD-SCLC, 99 who received CCRT were included in the analysis, comprising 74 patients in the early thoracic RT (ERT) and 25 in the late thoracic RT (LRT) group. After propensity score matching (PSM) based on RT timing, Kaplan-Meier survival analysis demonstrated that the ERT group had significantly longer median overall survival (OS) (20.0 Conclusions: In patients with LD-SCLC treated with CCRT, ERT was associated with improved survival without a significant increase in treatment-related toxicity. Although PCI did not confer a clear survival benefit, it may reduce the risk of brain metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.